ME00112B - Sferni aglomerati telitromicina,postupak za njihovo dobijanje i njihova primena u dobijanju farmaceutskih oblika - Google Patents

Sferni aglomerati telitromicina,postupak za njihovo dobijanje i njihova primena u dobijanju farmaceutskih oblika

Info

Publication number
ME00112B
ME00112B MEP-2008-201A MEP2008201A ME00112B ME 00112 B ME00112 B ME 00112B ME P2008201 A MEP2008201 A ME P2008201A ME 00112 B ME00112 B ME 00112B
Authority
ME
Montenegro
Prior art keywords
telithromycin
spherical agglomerates
microns
particle size
agglomerates
Prior art date
Application number
MEP-2008-201A
Other languages
English (en)
French (fr)
Unknown language (me)
Inventor
Jean Yves Godard
Valerie Rognon
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9549351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00112(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of ME00112B publication Critical patent/ME00112B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1688Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MEP-2008-201A 1999-08-26 2000-08-28 Sferni aglomerati telitromicina,postupak za njihovo dobijanje i njihova primena u dobijanju farmaceutskih oblika ME00112B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9910810A FR2797875B1 (fr) 1999-08-26 1999-08-26 Agglomerats spheriques de telithromycine, leur procede de preparation et leur application dans la preparation de formes pharmaceutiques
PCT/FR2000/002393 WO2001014393A2 (fr) 1999-08-26 2000-08-28 Agglomerats spheriques de telithromycine, leur procede de preparation et leur application dans la preparation de formes pharmaceutiques

Publications (1)

Publication Number Publication Date
ME00112B true ME00112B (me) 2010-10-10

Family

ID=9549351

Family Applications (2)

Application Number Title Priority Date Filing Date
MEP-2008-201A ME00112B (me) 1999-08-26 2000-08-28 Sferni aglomerati telitromicina,postupak za njihovo dobijanje i njihova primena u dobijanju farmaceutskih oblika
MEP-201/08A MEP20108A (en) 1999-08-26 2000-08-28 Spherical telithromycin clusters, method for the production and use thereof in the preparation of pharmaceutical forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
MEP-201/08A MEP20108A (en) 1999-08-26 2000-08-28 Spherical telithromycin clusters, method for the production and use thereof in the preparation of pharmaceutical forms

Country Status (34)

Country Link
US (1) US6825218B1 (enExample)
EP (1) EP1212336B1 (enExample)
JP (1) JP4871467B2 (enExample)
KR (1) KR100718222B1 (enExample)
CN (1) CN1183151C (enExample)
AR (1) AR025398A1 (enExample)
AT (1) ATE255590T1 (enExample)
AU (1) AU774385B2 (enExample)
BR (1) BR0013569B1 (enExample)
CA (1) CA2382497C (enExample)
CO (1) CO5190666A1 (enExample)
CZ (1) CZ2002594A3 (enExample)
DE (1) DE60006976T2 (enExample)
DK (1) DK1212336T3 (enExample)
EA (1) EA005080B1 (enExample)
ES (1) ES2209970T3 (enExample)
FR (1) FR2797875B1 (enExample)
HK (1) HK1049167B (enExample)
HR (1) HRP20020167B1 (enExample)
HU (1) HU229075B1 (enExample)
IL (2) IL148128A0 (enExample)
ME (2) ME00112B (enExample)
MX (1) MXPA02001988A (enExample)
NO (1) NO322622B1 (enExample)
PL (1) PL204100B1 (enExample)
PT (1) PT1212336E (enExample)
RS (1) RS50433B (enExample)
SI (1) SI1212336T1 (enExample)
SK (1) SK287588B6 (enExample)
TR (1) TR200200506T2 (enExample)
TW (1) TWI272949B (enExample)
UA (1) UA73523C2 (enExample)
WO (1) WO2001014393A2 (enExample)
ZA (1) ZA200201599B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902202D0 (sv) * 1999-06-10 1999-06-10 Astra Ab Production of aggregates
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
BR0215806A (pt) * 2002-07-19 2005-04-26 Aventis Pharma Sa Composição oral de telitromicina com paladar mascarado
US20040013737A1 (en) * 2002-07-19 2004-01-22 Philippe Becourt Taste masked oral composition of telithromycin
WO2004009059A1 (en) * 2002-07-19 2004-01-29 Aventis Pharma S.A. Taste masked oral composition of telithromycin
CA2516733C (en) * 2003-02-21 2011-09-27 The University Of Bath Process for the production of particles
US20050014706A1 (en) * 2003-07-14 2005-01-20 Kanakeshwari Falzari Method of treating tuberculosis
WO2007039914A2 (en) * 2005-10-06 2007-04-12 Alembic Limited Novel polymorphs of telithromycin
US20090075917A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched telithromycin
KR101324862B1 (ko) * 2011-07-12 2013-11-01 (주)에이에스텍 클로피도그렐 황산수소염의 구형 입자, 이를 포함하는 약학적 조성물 및 이의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3468336D1 (en) * 1983-06-22 1988-02-11 Univ Ohio State Res Found Small particle formation
JPH02227130A (ja) * 1989-02-28 1990-09-10 Taisho Pharmaceut Co Ltd 球形微小凍結粒子の製造法
FR2719587B1 (fr) * 1994-05-03 1996-07-12 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.

Also Published As

Publication number Publication date
HK1049167B (zh) 2005-08-19
NO322622B1 (no) 2006-11-06
EP1212336B1 (fr) 2003-12-03
KR20020033771A (ko) 2002-05-07
HRP20020167B1 (en) 2006-06-30
HRP20020167A2 (en) 2003-06-30
CN1183151C (zh) 2005-01-05
YU13202A (sh) 2004-09-03
DK1212336T3 (da) 2004-03-15
BR0013569B1 (pt) 2014-02-25
SK2532002A3 (en) 2002-09-10
EA200200294A1 (ru) 2002-08-29
NO20020926L (no) 2002-02-26
WO2001014393A2 (fr) 2001-03-01
FR2797875B1 (fr) 2001-10-19
JP2003507484A (ja) 2003-02-25
HK1049167A1 (en) 2003-05-02
CZ2002594A3 (cs) 2002-09-11
TR200200506T2 (tr) 2002-08-21
AR025398A1 (es) 2002-11-27
AU774385B2 (en) 2004-06-24
US6825218B1 (en) 2004-11-30
IL148128A (en) 2006-10-31
TWI272949B (en) 2007-02-11
PL204100B1 (pl) 2009-12-31
AU7018100A (en) 2001-03-19
ATE255590T1 (de) 2003-12-15
CN1371386A (zh) 2002-09-25
HUP0202842A2 (hu) 2003-01-28
EP1212336A2 (fr) 2002-06-12
HUP0202842A3 (en) 2003-03-28
MEP20108A (en) 2010-06-10
KR100718222B1 (ko) 2007-05-15
RS50433B (sr) 2009-12-31
ES2209970T3 (es) 2004-07-01
CA2382497A1 (fr) 2001-03-01
ZA200201599B (en) 2003-04-30
CO5190666A1 (es) 2002-08-29
CA2382497C (fr) 2011-06-28
JP4871467B2 (ja) 2012-02-08
DE60006976D1 (de) 2004-01-15
WO2001014393A3 (fr) 2001-06-21
MXPA02001988A (es) 2002-08-20
SI1212336T1 (en) 2004-04-30
PT1212336E (pt) 2004-04-30
BR0013569A (pt) 2002-05-14
SK287588B6 (sk) 2011-03-04
PL353137A1 (en) 2003-10-20
EA005080B1 (ru) 2004-10-28
IL148128A0 (en) 2002-09-12
UA73523C2 (uk) 2005-08-15
DE60006976T2 (de) 2004-10-21
NO20020926D0 (no) 2002-02-26
HU229075B1 (hu) 2013-07-29
FR2797875A1 (fr) 2001-03-02

Similar Documents

Publication Publication Date Title
ME00112B (me) Sferni aglomerati telitromicina,postupak za njihovo dobijanje i njihova primena u dobijanju farmaceutskih oblika
Qian et al. A new mechanism for nuclei formation in suspension crystallizers: the role of interparticle forces
BR9206996A (pt) Composição adequada para preparar esferóides por esferoidização processo para produzir um material em partículas processo para produzir uma forma de dosagem de sólido esferoidizado em partículas e forma de dosagem sólida
EP0383568A3 (en) Calcium phosphate fibers
SI2170279T1 (en) Methods for producing aripiprazole suspension and freeze-dried formulation
CN103238617B (zh) 一种噻虫胺增效可溶性颗粒剂及其制备方法
CN107902662A (zh) 一种高分散性高粘度硅酸镁铝无机凝胶的制备方法
JP2003511391A (ja) 構造化界面活性剤系
CN106698380B (zh) 一种利用贝壳制备的羟基磷灰石及其制备方法
CN105407742A (zh) 具有芳环体系的有机酸或酯的改进粉末制剂
CN108409753B (zh) 一种头孢噻肟钠球形晶体的制备方法
JP2003507484A5 (enExample)
MX9305539A (es) Procedimiento para la fabricacion de pellets a partir de un derivado de efedrina.
JP4940724B2 (ja) 脂質被覆物の製造方法
SK54593A3 (en) Benzenedimethanol suitable for micronisation
Paradkar et al. Crystal engineering and particle design for the powder compaction process
CN103215015A (zh) 硅酸镁锂基纳米流体及其制备方法
Matsunaga et al. Fabrication of hydroxyapatite microcapsules for controlled release of hydrophobic drug
ES2034805T3 (es) Procedimiento para la obtencion de pellets de derivados de xantina.
CN104093327B (zh) 改良的具有芳香环的有机酸或酯的粉末制剂
Fernandez Garcia et al. Histomorphometrical study of the submandibular gland ductal system in the rat
JP6427788B2 (ja) 芳香環系を有する有機酸アミドの改良された粉末配合物
JPH0515678B2 (enExample)
CN111936497A (zh) 制备匹莫迪韦盐酸盐半水合物的结晶形式的等温反应性结晶方法
CN108219747A (zh) 一种对植被具有缓蚀作用的融雪剂及其制备方法